Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
United States
/
Pharmaceuticals & Biotech
/
Gossamer Bio
GOSS
Gossamer Bio
Biotech Regulation And Cash Burn Will Constrain Future Prospects
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 7 Analysts
Published
12 Aug 25
Updated
16 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
US$1.25
53.6% overvalued
intrinsic discount
16 Aug
US$1.92
Loading
1Y
106.5%
7D
-0.5%
Author's Valuation
US$1.3
53.6% overvalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
US$1.3
53.6% overvalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-240m
96m
2016
2018
2020
2022
2024
2025
2026
2028
Revenue US$66.4m
Earnings US$10.8m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
50.02%
Biotech revenue growth rate
12.78%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
7.35%
Calculation
US$10.78m
Earnings '28
x
33.00x
PE Ratio '28
=
US$355.81m
Market Cap '28
US$355.81m
Market Cap '28
/
230.88m
No. shares '28
=
US$1.54
Share Price '28
US$1.54
Share Price '28
Discounted to 2025 @ 7.36% p.a.
=
US$1.25
Fair Value '25
